Shots:
- Synlogic & Caldera have agreed to merge in an all-stock transaction, forming a new holding company that will operate as Caldera Therapeutics & plans to list on Nasdaq under the ticker “CALD”
- Upon closing, Synlogic, Caldera, and private placement investors are expected to own ~2.3%, ~62.8%, and ~34.9% of the combined company, respectively, with Synlogic’s stake subject to net cash adjustment; closing is expected by early 2027
- Caldera also secured commitments for an upsized ~$278M private placement to fund P-II development of CLD-423 in ulcerative colitis & Crohn’s disease, with potential expansion into additional immune-mediated diseases
Ref: Businesswire | Image: Synlogic and Caldera | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
